Resultado de búsqueda
12 de may. de 2021 · Published May 12, 2021. N Engl J Med 2021;384: 1800 - 1809. DOI: 10.1056/NEJMoa2034975. VOL. 384 NO. 19. Abstract. Background. Tezepelumab is a human monoclonal antibody that blocks thymic stromal...
12 de ene. de 2022 · Biologic agents are efficacious add-on therapies for uncontrolled, severe eosinophilic asthma. These therapies represent major breakthroughs, significantly decreasing exacerbation rates and ...
7 de may. de 2024 · The 2022 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee.
7 de may. de 2024 · The 2023 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee.
2 de mar. de 2021 · Last year’s Update in Asthma highlighted the need to integrate multidisciplinary advances, leading to better appreciation of epidemiological evidence, new paradigms for effective preventative strategies, and to move treatment focus to the biological underpinnings of asthma.
13 de ene. de 2022 · This review outlines recent insights into type 2 inflammation in asthma and the currently available biologic treatments, including their mechanism of action, effi- cacy, and safety in...
17 de dic. de 2021 · Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine. 3 It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase 2 and 3 clinical trials, which included a ...
